Clinical Trials
26 trialsClinical Study of 18F-Exendin-4 in Insulinoma
Sichuan Provincial People's Hospital
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Stanford University
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Eastern Cooperative Oncology Group
LTW
Laser Tissue Welding, Inc.
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
University of Southern California
GLP-1-AHH
Radboud University Medical Center
Blinded Resection in Case of the Pancreatic Insulinoma
Vishnevsky Center of Surgery
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
National Cancer Institute (NCI)
Cinacalcet to Treat Familial Primary Hyperparathyroidism
National Institutes of Health Clinical Center (CC)
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
National Cancer Institute (NCI)
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
University of Iowa
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Federation Francophone de Cancerologie Digestive
Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients
University Hospital, Basel, Switzerland
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Delcath Systems Inc.
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Novartis
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
National Cancer Institute (NCI)
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
National Cancer Institute (NCI)
Laparoscopy to Remove Pancreatic Tumors (Insulinomas)
National Institutes of Health Clinical Center (CC)